Despite existing data failing to conclusively determine if the co-inhibition or elimination of PD-1 and CTLA-4 would influence patient prognosis significantly, the emergent sensitivity of these immune checkpoints in the risk model carves a new path for advancing immunotherapy for ccRCC. Here, PDCD1 is linked to nonpapillary renal cell carcinoma.